Cholesterol

Beef produced from the hand-chosen Black Angus cattle born and raised on the La Cense Beef ranch in Montana are free of antibiotics and hormones and graze upon grass from pesticide free pastures.

La Cense cattle also benefit from a stress-free environment, spending their entire lives on the pristine pastures of this 88,000-acre ranch and feeding on new grass and plants everyday that are at least 10 inches high.

This ensures that cattle face no stress when foraging.

Additionally, grass is the natural diet of cattle, which are ruminants.

Cattle do not normally eat grain, nor are they designed to digest this feed, meaning that an exclusive diet of grass represents a more humane and ethical treatment of these animals.

Furthermore, as La Cense Beef is not sourced from a consortium of ranches but produced exclusively from the cattle born and raised on the ranch, consumers are ensured that food safety issues are minimized, as La Cense cattle never come into contact with cattle from other herds.

Last, but not least, grass fed beef offers a truer, cleaner beef flavor.

"Grain fed beef derives its flavor from the fat, not from the meat itself as does grass fed beef," says Hoffman.

"The result is a more authentic beef taste, reminiscent of the way that beef used to taste before the industrialization of agriculture.

You have a much cleaner aftertast...

North America, which accounts for 45 per cent of global pharmaceutical sales, grew 8.3 per cent to $290.1 billion in 2006, up from 5.4 per cent in the previous year.

Generics constitute almost half of the volume sales and has a market in the US valued at $54 billion, according to IMS Health.

Legislative attempts to control drug expenditures, the increased influence of payers to drive more cost-effective healthcare, generics competition, and the introduction of new biosimilars will impact US prescription growth in five years.

In 2006, prescription volume of unbranded generics grew by 13 per cent and sales of unbranded generics grew by 22 per cent, especially due to generics entering the market for Zoloft and Zocor.

“Branded blockbusters such as Norvasc and Ambien are set to lose patent protection in 2007.

US pharmaceutical sales would growth at 6-9 per cent through 2010 as a result of the influence of lower-priced generics,” predicts IMS Health.

It is estimated that $80 billion worth of drugs are set to go off-patent progressively by 2010-15.

Share Your Comments Print this page Mail to friend .homeline { FONT-FAMILY: arial; FONT-SIZE: 10px; color:black; FONT-WEIGHT:bold; } .homeline1 { F...